An Extension Trial to Assess the Safety of Re-dosing of Iron Isomaltoside/Ferric Derisomaltose (Monofer®/Monoferric®)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 103 participants.
Also called NCT02962648
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 103 participants
- Sponsor
- Registry
-
NCT02962648
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT02962648. Allocation not applicable; no masking; primary purpose treatment. Start 2017-01-09 (actual); primary completion 2018-06-12 (actual). Results posted on 2020-03-10.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- An Extension Trial to Assess the Safety of Re-dosing of Iron Isomaltoside/Ferric Derisomaltose (Monofer®/Monoferric®)
- Acronym
- FERWON-EXT
- Condition
- Iron Deficiency Anemia
- Condition
- Iron Deficiency Anaemia
- Intervention (Drug)
- Iron isomaltoside/ferric derisomaltose
- Lead sponsor
- Pharmacosmos A/S
Record details
- Record id
cardio:ct-nct02962648- Content hash
59a6d0f2640091a29d64d9ccf7e5e9f7d6660f3c216329fb45bd1140112d1891